Brief: OSE Immunotherapeutics's Tedopi® Receives U.S Patent Notice Of Allowance

Ose Immunotherapeutics SA

07/09/2021 06:41

Sept 7 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS RECEIVES U.S. PATENT NOTICE OF
ALLOWANCE
FOR TEDOPI®
    * FURTHER STRENGTHENS GLOBAL INTELLECTUAL PROPERTY PORTFOLIO
FOR
TEDOPI® IN NON-SMALL CELL LUNG CANCER UNTIL 2035
    * ATALANTE 1 CLINICAL TRIAL AIMS AT EVALUATING BENEFIT OF
TEDOPI®
IN HLA-A2 POSITIVE NSCLC PATIENTS AT INVASIVE STAGE IIIB OR
METASTATIC STAGE IV, AS 2ND OR 3RD LINE TREATMENT FOLLOWING
CHECKPOINT INHIBITOR FAILURE
    * TEDOPI® TREATMENT IS COMPARED TO DOCETAXEL OR PEMETREXED
CHEMOTHERAPY (CT) TREATMENTS, WITH OVERALL SURVIVAL AS PRIMARY
ENDPOINT
    * WE CONTINUE TO DEVELOP TEDOPI® IN NSCLC AFTER FAILURE FROM
IMMUNE CHECKPOINT INHIBITORS (ICI) AS WELL AS IN OTHER CANCER
INDICATIONS, IN COMBINATION WITH ICIS OR WITH CHEMOTHERAPY

Source text for Eikon:  ID:nBw3PwTcga 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))